Breakthrough in Pediatric Skin Disease: First Clinical Trial Shows 66% Symptom Reduction with QRX003
First-ever clinical study reveals dramatic improvement in pediatric peeling skin syndrome. QRX003 achieves 66% reduction in severity scores. See complete data.
|
![]() |